Monday, December 23, 2024
HomeTagsIDEAYA Biosciences

IDEAYA Biosciences

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

IDEAYA Biosciences, Inc., a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced selection of a monotherapy expansion dose...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics